Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

4.03USD
21 Apr 2017
Change (% chg)

$-0.16 (-3.82%)
Prev Close
$4.19
Open
$4.19
Day's High
$4.19
Day's Low
$3.81
Volume
843,992
Avg. Vol
459,256
52-wk High
$9.45
52-wk Low
$1.51

Latest Key Developments (Source: Significant Developments)

Immunogen files for mixed shelf of up to $200 mln – SEC filing
Friday, 3 Mar 2017 04:23pm EST 

Immunogen Inc :Immunogen Inc files for mixed shelf of up to $200 million – sec filing.  Full Article

Immunogen sees FY 2017 revenue $70 mln to $75 mln
Friday, 17 Feb 2017 06:30am EST 

Immunogen Inc : Immunogen reports recent progress and operating results for six-month period and quarter ended December 31, 2016 . Sees FY 2017 revenue $70 million to $75 million . Immunogen Inc - first patient enrolled in phase 3 forward I trial of mirvetuximab soravtansine . Immunogen Inc - sees 2017 revenues between $70 million and $75 million . Immunogen Inc - sees 2017 operating expenses between $175 million and $180 million . Immunogen Inc -sees cash and marketable securities at December 31, 2017 between $35 million and $40 million .Immunogen - expects current cash plus expected cash revenues from partners and collaborators will enable company to fund operations into Q2 of 2018.  Full Article

US appeals court dismisses Phigenix appeal in patent lawsuit vs Immunogen
Monday, 9 Jan 2017 09:41am EST 

Immunogen Inc : u.s. Appeals court dismisses phigenix inc appeal in patent infringement lawsuit against immunogen inc -- court ruling . u.s. Court of appeals for federal circuit says phigenix lacks standing to sue because it lacked sufficient proof of injury . Lawsuit related to patent intended to help combat a variety of cancers -- ruling Further company coverage: [IMGN.O].  Full Article

Immunogen quarterly loss $0.51 per share
Friday, 28 Oct 2016 06:39am EDT 

Immunogen Inc : Immunogen reports financial results for quarter ended September 30 and reviews business highlights . Quarterly loss per share $0.51 . Quarterly revenue $7.7 million versus $14.9 million . Immunogen Inc - Expected revenues for six months ending December 31, 2016 now projected to be between $25 million and $30 million . Immunogen Inc - Net loss for six months ending December 31, 2016 now expected to be between $70 million and $75 million .Immunogen - Operating expenses in quarter correspondingly include $4.1 million restructuring charge,includes costs related to 17 percent workforce reduction.  Full Article

Immunogen: Will reduce workforce by 17 pct
Thursday, 29 Sep 2016 04:01pm EDT 

Immunogen Inc : Company will reduce its workforce by 17 pct and seek to partner its non-core b-cell lymphoma programs . Through this plan, Immunogen will realize significant cost savings over next two years in headcount, program, and support activities . These savings will include approximately $11 million per year relating to elimination of 65 positions . Expects to achieve previously-stated goal of funding operations through analysis of mirvetuximab soravtansine pivotal trial,into mid-2018 . As a result of workforce reduction, immunogen will record a one-time charge totaling approximately $3.5 million .As part of this effort and prioritization of its ign programs, will seek to monetize its non-core b-cell assets through partnering with interested parties.  Full Article

Immunogen announces update to financial results year ended June 30, 2016 - SEC filing
Thursday, 25 Aug 2016 03:47pm EDT 

Immunogen Inc: Announces update to financial results for the quarter and year ended June 30, 2016 - SEC filing . Due to info that became available related to potential liability to a contract manufacturer, additional expense accrual was required . Due to the additional expense accrual, financial results have been adjusted .FY net loss increased to $144.8 million or $1.67 per share, will be reported as such in 10-K filing.  Full Article

Immunogen Q4 loss per share $0.51
Thursday, 4 Aug 2016 06:30am EDT 

Immunogen Inc : Q4 loss per share $0.51 . Immunogen reports fourth quarter and fiscal year 2016 financial results and provides quarterly business update . Q4 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Phase 3 forward I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end. . Ended fiscal year with approximately $245 million in cash . For six months ending December 31, 2016, Immunogen expects revenues to be between $40 million and $45 million .For six months ending December 31, 2016, Immunogen expects net loss to be between $55 million and $60 million.  Full Article

ImmunoGen announces pricing of $100 mln offering of Senior Notes
Wednesday, 15 Jun 2016 08:58am EDT 

Immunogen Inc : Sale of notes is expected to result in $96.7 million net proceeds to Immunogen . Interest will be payable semi-annually in arrears on january 1 and july 1 of each year, beginning january 1, 2017 . Sale of notes expected to result in proceeds of $111.2 million if initial purchasers exercise option to purchase additional notes in full . Notes will be senior unsecured obligations of Immunogen, and will bear interest at a rate of 4.50% per year .Immunogen announces pricing of $100 million offering of 4.50% convertible senior notes due 2021.  Full Article

Immunogen announces proposed $100 mln offering of convertible senior notes
Monday, 13 Jun 2016 04:01pm EDT 

Immunogen Inc : Immunogen announces proposed $100 million offering of convertible senior notes due 2021 . Says notes will be senior unsecured obligations of immunogen, and interest will be payable semi-annually .Immunogen Inc says intends to use net proceeds of offering for its operations, including but not limited to clinical trial expenditures.  Full Article

ImmunoGen reports positive early-stage data on ovarian cancer drug
Wednesday, 18 May 2016 05:01pm EDT 

Immunogen : Reports efficacy and safety data from a 46 patient cohort of mirvetuximab soravtansine in frα-positive ovarian cancer . Company preparing to meet with FDA in early 3q 2016; targeting initiation of phase 3 study in 4q2016 .Plan to have phase 3 testing of mirvetuximab soravtansine up and running by year end.  Full Article

More From Around the Web

BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate

* Immunogen has elected not to exercise its late stage co-development option for the us-market with Biotest's antibody-drug conjugate (BT-062) Source text for Eikon: Further company coverage: (Gdynia Newsroom)